All news

ResMed beats EPS by 13% as analysts lift targets

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

ResMed beat statutory profit expectations by 13% with first-quarter EPS of US$2.92, while revenue of US

Read original source

RMD company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.